# A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene

> **NCT05497453** · PHASE1,PHASE2 · TERMINATED · sponsor: **Omega Therapeutics** · enrollment: 24 (actual)

## Conditions studied

- Hepatocellular Carcinoma
- Solid Tumor
- Hepatocellular Carcinoma Non-resectable
- Hepatocellular Carcinoma Recurrent
- Hepatocellular Cancer
- Liver Cancer
- Liver, Cancer Of, Non-Resectable

## Interventions

- **DRUG:** OTX-2002
- **DRUG:** Tyrosine kinase inhibitor One
- **DRUG:** Tyrosine kinase inhibitor Two
- **DRUG:** Checkpoint Inhibitor, Immune

## Key facts

- **NCT ID:** NCT05497453
- **Lead sponsor:** Omega Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-08-19
- **Primary completion:** 2024-11-21
- **Final completion:** 2024-11-21
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** Sponsor decision to terminate after monotherapy dose escalation.
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05497453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05497453, "A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT05497453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*